anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a drug for treating heart failure, and specially relates to a traditional Chinese medicine, which is prepared from traditional Chinese herbals, for treating heart failure. The traditional Chinese medicine is characterized in that the effective component (crude drug) is composed of the following raw materials by weight: 15 to 25 grams of radix astragali, 10 to 20 grams of red sage root, 5 to 15 grams of ginseng, 5 to 15 grams of lily, 5 to 15 grams of dwarf lilyturf tuber, 5 to 15 grams of dry ginger, 5 to 15 grams of monkshood, and 5 to 15 grams of fried hyacinth bean. In the formula the components cooperate with each other to generate a synergic effect: radix astragali, ginseng, and red sage root all have the functions of replenishing qi, tonifying qi, and eliminating swelling; lily and dwarf lilyturf tuber both have the functions of moistening lung to arrest cough, tonifying stomach, engendering liquid, clearing away the heart-fire, relieving restlessness, and tranquilizing; dry ginger has the functions of warming the middle and dispelling the cold; monkshood has the functions of regulating qi and resolving depression; and fried hyacinth bean has the functions of tonifying the spleen and resolving dampness. Through the breathing function, the effective medicinal components are absorbed by human body, enter the lung from the nasal cavity, are resolved in blood through a dialysis effect, then arrive at the left atrium along with the blood circulation, and finally absorbed by myocardial cells. The effect medicinal components can improve the blood circulation state of a heart failure patient, and effectively treat the heart failure patient. The traditional Chinese medicine has the advantages of low cost and simple formula, and can be prepared by a single person.
Hepatic cirrhosis is considered a severe health problem in Mexico, since it is the third mortality cause in working-age people and there is no 100% effective treatment. Cirrhosis is characterized by an exacerbated increase of collagen in liver parenchyma, replacing the hepatocytes and thus provoking liver failure. This is one of the reasons why we have used a gene therapy through specific delivery to cirrhotic livers of the gene of human urokinase plasminogen activator (huPA), which activates mechanisms that induce the degradation of excess cellular matrix and stimulate hepatocyte proliferation, obtaining thus a fast re-establishment of the liver function. In the instant invention, the modified human uPA gene was inserted in the adenoviral vector (pAd-ΔhuPA), because it is not secreted and does not provoke hypercoagulation or spontaneous internal bleedings. Moreover, data from the bio-distribution essay with an adenoviral vector with reporter gene β-gal have shown liver specificity as the target organ of the vector. Using ELISA, huPa protein was detected in liver homogenates (4500 pg/ml) in animals treated with pAd-ΔhuPA and was also intracellularly detected through immunochemistry in liver cuts (80% positive cells). huPa induced a dramatic fibrosis reduction (85%) on day 10 of vector administration, compared to control cirrhotic rats and 55% hepatocyte proliferation increase. Liver function tests (ALT, AST, alkaline phosphatase and bilirubin) dropped to nearly normal levels and hepatocyte proliferation was observed. Because of the two beneficial event cascades, gene therapy with modified huPA can be developed as a definite potential treatment for patients with liver cirrhosis.
The invention discloses an amber-containing Chinese medicine decoction piece composition preparation for somnolence. The amber-containing Chinese medicine decoction piece composition preparation is a compound Chinese medicine decoction piece preparation and comprises components in parts by mass as follows: 100 parts of amber, 100 parts of antelope's horns, 100 parts of radix codonopsis, 100 parts of poria cocos, 100 parts of radix polygalae and 100 parts of liquorice. The invention further discloses a preparation method of the amber-containing Chinese medicine decoction piece composition preparation for somnolence. The preparation method comprises steps as follows: raw materials are soaked, washed, dried, impacted, collided, rubbed, sheared, ground and broken, ultrafine amber powder with nano-scale of 1-65 nm is prepared, the soaking time is 35-40 minutes, the washing water pressure is 2-12 MPa, and the raw materials are embrittled at the temperature of subzero 19 DEG C before impacting. The invention further discloses an application package of the amber-containing Chinese medicine decoction piece composition preparation for somnolence. Amber, antelope's horns, radix codonopsis, poria cocos, radix polygalae and liquorice are proportionally packaged into bags. The amber-containing Chinese medicine decoction piece composition preparation has good effects on symptoms such as dizziness, malaise, palpitation and insomnia and the like.
The present invention provides a magnetic microsphere carrier medicine-doxy rhodol magnetic microsphere, and a preparation method thereof. The doxy rhodol magnetic microsphere contains 1 to 2 mg of nanometer Fe3O4 magnetic granules, 2 to 10 mg of alpha 1-acid glycoprotein, 1 to 2 mg of docetaxel, and oleic acid. The medicine of the present invention has favorable magnetic response performance in that the medicine is concentrated at a target region under the condition of target positioning of an external magnetic field or an internal magnetic field, but the other positions have very low concentration and even no concentration. Thus, the killing efficiency to tumors is enhanced, toxic and side effects on a whole body caused by chemotherapeutics are reduced greatly, and heavy economic burden of patients is lightened. The present invention has an industrial production prospect. After commercialization, a novel antitumor target medicine can be provided, and patients with tumors can benefit.
The invention relates to the technical field of computer data management, and provides a recipe management method and a recipe management device. The recipe management method comprises the following steps: obtaining a recipe; determining a food nutrition evaluation value corresponding to food materials contained in the recipe; determining the corresponding duty ratio of food materials contained in the recipe; determining a corresponding recipe nutrition evaluation value based on the food nutrition evaluation value and the duty ratio; outputting the recipe and the recipe nutrition evaluation value. According to the recipe management method, the food materials included in the recipe are determined, and further, the food material nutrition evaluation value corresponding to the food materials can be determined. The recipe nutrition evaluation value may be determined based on the food nutrition evaluation value and the ratio of food in the recipe. The user can intuitively judge whether the recipe is suitable for being eaten by himself or herself through the recipe nutrition evaluation value, so that the recipe capable of improving the physical condition can be better selected. And as the nutrition evaluation value of the recipe is related to the ratio of each food material, the recipe is further subjected to finer management so as to improve the reference value of the recipe to a user.
PCT No. PCT/JP94/00819 Sec. 371 Date Nov. 21, 1995 Sec. 102(e) Date Nov. 21, 1995 PCT Filed May 20, 1994 PCT Pub. No. WO94/28130 PCT Pub. Date Dec. 8, 1994This invention relates to a gene encoding a polypeptide having pre-B cell growth-supporting ability, and an adhesion molecule of the polypeptide consisting of 318 amino acid residues having pre-B cell growth-supporting ability, or a part of it. Said adhesion molecule is produced by preparing transformants such as microorganism or cells by transforming a host cell with a vector containing said gene and culturing said transformants. The above gene encodes the novel adhesion molecule enhancing the pre-B cell growth-supporting ability on the bone marrow cell and the synovial cell derived from patients with rheumatoid arthritis (RA) and multiple myeloma (MM). The homogeneous and purified adhesion molecule having pre-B cell growth-supporting ability can be produced in large quantities, and therefore it is possible to identify multiple myeloma (MM) and rheumatoid arthritis (RA), and also prepare reagents for the clinical diagnosis thereof.\!
Responsive nanomaterials hold significant promise in the treatment of bacterial infections by recognizing internal or external stimuli to achieve stimuli-responsive behavior. In this study, we present an enzyme-responsive polyelectrolyte complex micelles (PTPMN) with α-helical cationic polypeptide as a coacervate-core for the treatment of Escherichia coli (E. coli) infection. The complex was constructed through electrostatic interaction between cationic poly(glutamic acid) derivatives and phosphorylation-modified poly(ethylene glycol)-b-poly(tyrosine) (PEG-b-PPTyr) by directly dissolving them in aqueous solution. The cationic polypeptide adopted α-helical structure and demonstrated excellent broad-spectrum antibacterial activity against both Gram-negative and Gram-positive bacteria, with a minimum inhibitory concentration (MIC) as low as 12.5 μg mL-1 against E. coli. By complexing with anionic PEG-b-PPTyr, the obtained complex formed β-sheet structures and exhibited good biocompatibility and low hemolysis. When incubated in a bacterial environment, the complex cleaved its phosphate groups triggered by phosphatases secreted by bacteria, exposing the highly α-helical conformation and restoring its effective bactericidal ability. In vivo experiments confirmed accelerated healing in E. coli-infected wounds.
PURPOSE: To extremely efficiently immunize fowls due to the specific presence of an immunogen in a bursa of Fabricius during the capturing period of the immunogen by administering the immunogen to the whole cloacae of a fetus of fowls during the hatching period. CONSTITUTION: This method for immunizing fowls is to administer an immunogen source to the whole cloacae of a fetus of fowls (preferably a chicken) during the hatching period. The administration period is preferably about 18 days of age after the hatching when the fetus starts pulmonary respiration to a time just before the hatching when a urodeal membrane is present. A method for directly injection from the sharpest end of an egg during the hatching period with an injection syringe, etc., are preferred as the method for administration. In this case, eggshell can be repaired to normally hatch the egg by closing an inoculation needle track with paraffin, etc. For example, Salmonella pullorum which is a causative virus for salmonellosis or a causative virus for Newcastle disease can be used as the immunogen.
Although pharmacological and psychosocial treatments for alcohol use disorders (AUDs) exist that improve outcomes over natural recovery (Finney et al., 2013), outcomes are still modest. Identifying mechanisms of behavior change (MOBCs) that lead to successful outcomes may be critical for efforts to improve existing treatments or to better match patients with particular treatments. The goal of the proposed research is to conduct a randomized clinical trial to systematically examine pretreatment neurocognitive and behavioral characteristics and changes in brain function over time during two empirically supported treatments for AUD. One hundred forty treatment-seeking individuals with an AUD will be randomized to receive either 8 weeks of Cognitive Behavioral Treatment (CBT) or Mindfulness Based Treatment (MBT) after receiving 4 weeks of a platform treatment that focuses on enhancing motivation to change. Neurocognitive and behavioral characteristics will be measured using neuroimaging, comprehensive behavioral assessments, and patient self-reports. To establish the temporal relationship between changes in drinking and changes in these MOBCs, patients will be assessed at: (a) baseline; (b) four weeks into treatment; (c) immediately post-treatment; and (d) 9- and 15-months post-baseline. Self-report measures and behavioral tasks will be administered at monthly intervals during treatment; and fMRI will be collected at baseline, and at 3, and 9-months post baseline. The primary aim of the study is to examine the effects of the treatments on three hypothesized mechanisms: craving/regulation of craving, cognitive and behavioral control, and regulation of affect/arousal. The secondary aim will identify neurocognitive and behavioral baseline characteristics predictive of reductions in drinking over time and differential patterns of response to CBT or MBT.
Electroencephalographic reactivity (EEG-R) is a promising early predictor of arousal in comatose patients after cardiac arrest. Despite recent guidelines advocating for the integration of EEG-R into the multimodal prognostication model, EEG-R testing methods remain heterogeneous across studies. While efforts towards standardization have been made to reduce interrater variability by the development of quantitative approaches and machine learning models, future validation studies are needed to increase clinical applicability. Furthermore, the specific neurophysiological mechanisms and neuroanatomical correlates underlying EEG-R are not fully understood. In this narrative review, we explore the value and possible mechanisms of EEG-R, focusing on post-cardiac arrest comatose patients. We aim to discuss the current standard of knowledge and future directions, as well as elucidate possible implications for patient care and research.
BACKGROUND: CircRNAs are implicated in the tumorigenesis of various human cancers. This study aims to explore how circ_0003356 contributes to the development of gastric cancer (GC).
METHODS: Circ_0003356 expression was analyzed in GSE184882 dataset and validated in our cohort of GC patients and human GC cell lines. The correlations between circ_0003356 levels and prognostic parameters were analyzed. The contribution of circ_0003356 in GC cell malignant behaviors such as cell survival, apoptosis and invasion were investigated by circ_0003356 overexpression in GC cell lines. The downstream targets of circ_0003356 were predicted and verified in vitro and in vivo. The in vivo function of circ_0003356 was studied as well in a xenograft mouse model.
RESULTS: Circ_0003356 expressed at a low level in human GC tissues and cells, which was closely associated with poor outcome of GC patients. Circ_0003356 overexpression induced GC cell apoptosis while depressed the growing, migration and invasive abilities through miR-556-5p/FKBP5 axis. In vivo model showed retarded tumor growth when circ_0003356-overexpressed cells were inoculated.
CONCLUSION: Circ_0003356 is identified as a potential biomarker of the prognosis of human gastric cancer, and circ_0003356/miR-556-5p/FKBP5 axis could be a promising target in gastric cancer treatment.
Reactive oxygen species generated via reperfusion cause lipid damage and induce lipid peroxidation, leading to cerebral ischemia/reperfusion injury and exacerbation of cerebral infarction. Lipid radicals are key molecules generated during lipid peroxidation. Therefore, understanding the spatiotemporal behavior of lipid radicals is important to improve the therapeutic outcomes of cerebral infarction. However, the behaviors of lipid radicals in the brain remain unclear. In this study, we aimed to evaluate the distribution of radioactivity in a transient middle cerebral artery occlusion (tMCAO) model using lipid radical detection probe [125I]1 to assess the behaviors of lipid radicals after cerebral ischemia/reperfusion. The tMCAO model administered [125I]1 exhibited significant differences in the timing and location of radioactivity accumulation between the ischemic and non-ischemic regions. Liquid chromatography/mass spectrometry analysis identified the lipid radical adducts formed by the reaction of 1 with the lipid radicals generated after reperfusion. More adducts were detected in the ischemic region samples than in the non-ischemic region samples. Therefore, 1 successfully detected the lipid radicals generated after cerebral ischemia/reperfusion. Overall, this study demonstrates the potential of nuclear medical imaging using radiolabeled 1 to detect the lipid radicals generated after cerebral ischemia/reperfusion. Our approach can aid in the development of new therapeutic agents scavenging lipid radicals after cerebral reperfusion by facilitating the determination of therapeutic efficacy and optimal administration period.
OBJECTIVES: This study aimed to review the blood stream infections of major burn patients in a tertiary care burn unit to determine the most prevalent infecting organisms in order to have a better empirical therapy protocol.
METHODS: This retrospective study analysed the blood stream infection of 155 major burn (>20% Total Body Surface Area [TBSA]) patients in Khoula Hospital, Muscat, Oman between January 2014 to December 2019.
RESULTS: The median age was 33 years and 57.42% of patients were male. The median TBSA was 38%, mortality was 25.16% and 50.9% of patients had positive blood cultures. The expired patients had higher TBSAs, Abbreviated Burns Severity Index scores and earlier first positive blood cultures. Candida was commonly grown in all the blood cultures, but the most prevalent organisms were Acinetobacter, Staphylococci, Klebsiella, Enterococcus and Pseudomonas. All Acinetobacter species are multidrug resistant. Of the 17 patients who had Kelbsiella grown in the blood culture, 8 grew multidrug-resistant Klebsiella. Only 4 patients' blood cultures grew methicillin-resistant Staphylococcus aureus. The number of blood culture samples taken ranged between 1-28 (median = 6). The first positive blood culture showed that Staphylococcus epidermidis and Acinetobacter were the most common infecting organisms.
CONCLUSIONS: Multidrug-resistant Acinetobacter was the most predominant microorganism grown from the blood cultures of major burn patients in a tertiary care burn unit. Empirical therapy should include antibiotics that are effective against this organism to reduce the mortality.
Open bite malocclusion is considered one of the most difficult orthodontic problems to correct because it appears as a result of the interaction of numerous etiological factors (genetic, dental, skeletal, functional, soft tissue, and habit) that contribute to its development. Various therapeutic approaches have been proposed for the treatment of an anterior open bite. These approaches vary depending on the causative factors and involve myotherapy, preventive treatment, functional therapy, orthognathic surgery, and orthodontic treatment using anterior teeth extrusion or posterior teeth intrusion. Among the non-surgical orthodontic treatment methods are the temporary anchorage devices (TADs) including miniplates and miniscrew or micro-screw implants. The intrusion of posterior teeth with temporary anchorage devices was suggested to lead to decreased lower facial height by a counterclockwise rotation of the mandible; this may resemble the orthognathic surgery outcomes for any open bite patients. To the best of the investigators current knowledge, this is the first randomized controlled trial evaluating the effect of molar intrusion in adolescence and adult patients in the permanent dentition stage.
CKD patients with eGFR ≥ 60 ml∙min-1∙ (1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
This is a prospective cohort, single centre, single-blinded study looking at a population of women post vaginal surgery with vaginal packing that is either coated with estrogen cream or 0.25% Bupivacaine + epinephrine (local anesthetic). Patients who have booked vaginal surgery for prolapse repair will be invited to participate in this study. A document describing the study will be provided for reading and will include the consent for the study. At the end of surgery, a vaginal pack is placed to decrease potential bleeding post surgery. At this time, patients will receive either vaginal packing with estrogen, or, the vaginal packing with 0.25% bupivacaine + epinephrine, according to physician preference. Patients and the nurses caring for them post surgery will be blinded as to which group the patient has been assigned to. The nurses in the recovery room and post operative ward will ask patients post surgery the day of surgery, (POD#0, two and six hours post OR) and POD#1 to rate the patients' surgical pain with a standardized, validated VAS pain score. Secondary outcomes will be recorded: the amount of analgesics used in hospital after surgery, intra-operative blood loss, post operative hemoglobin, the number of days until the patient is able to void, the amount of analgesics used at home after surgery (patients will be asked to keep a record of the total number of oral analgesic pain tablets used and on which day post surgery they stopped using pain medications) and other post surgical complications. Data will be stored in a secure, password protected desktop on site. Each patient will be assigned a unique number which can be traced back to a master file which will include patient identifiers (name, MRN, DOB). Data will be analyzed with the appropriate statistical tests. There are no additional tests or visits for patients. Patient study assignment will be disclosed to them at the 6 week routine post surgical examination/assessment visit.
PURPOSE:To selectively bond and hold specified lectin and lectin analogues by bonding an oval bumin saccharide chain to a methacrylate-based polymer having epoxy groups to synthesize a saccharide chain bonded resin. CONSTITUTION:A saccharide chain is allowed to react with ammonium acetate and sodium cyanoborate in an alcohol medium to form an aminosaccharide chain deriv. This deriv. is allowed to react with epoxy groups of a methacrylate- based polymer by the ring opening reaction of the epoxy groups in an alkaline state. By the reaction, the deriv. is bonded to the polymer to synthesize a saccharide chain bonded resin. Since the resin bonds selectively to specified lectin and lectin analogues, the resin can be used to separate and purify lectin and lectin analogues.